Repros Receives Guidance From FDA Regarding Continued Buildup Of Androxal(R) In Hypogonadal Men
The Company's information supports the solution that the abrogating feedback of exogenous testosterone administered by any route suppresses the hypothalamic-pituitary axis and hence spermatogenesis. The conversation with the FDA focused on two issues. Firstly, the FDA requested that the Association suggest a tab that larger defines the population of individuals for whom Repros believes Testament assist from the applicability of Androxal.
The FDA requested that the Partnership feed such hash and provided the FDA finds the submission adapted no further clarifying competition regarding the communication for Androxal may be required.
During the succession of the concourse Repros famous that whether the FDA concurred with the indication proposed by the Business, Repros would analogous to interrogate a especial protocol assessment (SPA). The FDA responded that the issues noted above should be resolved first off before undertaking a protocol audit. On the ring for Repros were Dr.
Jean Fourcroy MD, Repros Board member and former medical officer at the division of Reproductive and Urologic Products at the FDA (CDER), Dr. Andre T. Guay MD, Centre for Sexual Servicing (Endocrinology), Lahey Clinic (Dr. Guay has authored copious publications on the benefit of Clomid in the treatment of secondary hypogonadism), Dr.
Ronald Wiehle, VP of R&D at Repros and Joseph Podolski, Head of the state and CEO. In this balanced 200 patient analysis, at six months of exposure, exogenous testosterone (Androgel) suppressed both luteinizing hormone (LH) and follicle stimulating hormone (FSH) in a statistically meaningful means.
Everyone of these hormones was suppressed by higher quality than 60% compared to baseline (p equivalent 0.0001). In a subsequent read Repros correlated the reductions of FSH seen with exogenous testosterone with suppression of sperm counts. The change between the Androxal bevy and the Testim congregation achieved statistical Importance (p 0.01), yet though this was a diminutive co-pilot peruse.
As expected, Androxal improved FSH, the hormonal Chauffeur of spermatogenesis and Testim suppressed FSH as evidenced by the suppression of spermatogenesis. The antithesis in FSH between the two treatment groups besides achieved statistical significance at months three and six (p 0.02). Supportive of Repros' counsel is a interpret reported in the Magazine of Andrology, Volume.
22 No. Amory et al. In that article it was noted that after 6 months of treatment of regular men with an exogenous testosterone Potion (50 mg weekly injection) that maintained Forenoon testosterone levels within the typical area, sperm counts were reduced by 60%.
In the contingency of a dose that produced morning testosterone levels slightly above the conventional compass (100 mg weekly injection) azoospermia (no sperm) was induced in roughly 50% of the mean subjects. Repros extremely proposed the advantage of Androxal in a pulsed fashion to reverse hypogonadism induced by either drugs or physical dispute in younger men. Though the FDA understood this exercise the Agency chose to limelight the debate on the larger sign. Joseph S.
Podolski, President and CEO of Repros, noted, "We are encouraged by the agape and constructive discussion exhibited by the FDA during the teleconference. We contemplate forward to providing the FDA with the requested materials in the alongside hardly any weeks." The FDA noted once they be told the Company's materials that Repros could expect a well timed response. Source Repros Therapeutics Inc.
Please donate to the Doctors Without Borders Haiti Quiz.